A191420 logo

TegoScience Stock Price

Symbol: KOSDAQ:A191420Market Cap: ₩134.2bCategory: Pharmaceuticals & Biotech

A191420 Share Price Performance

₩16,790.00
830.00 (5.20%)
₩16,790.00
830.00 (5.20%)
Price ₩16,790.00

A191420 Community Narratives

There are no narratives available yet.

A191420 Community Fair Values

    Recent A191420 News & Updates

    No updates

    TegoScience Inc. Key Details

    ₩6.8b

    Revenue

    ₩2.0b

    Cost of Revenue

    ₩4.8b

    Gross Profit

    ₩1.5b

    Other Expenses

    ₩3.3b

    Earnings

    Last Reported Earnings
    Mar 31, 2025
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    418.33
    Gross Margin
    71.08%
    Net Profit Margin
    49.27%
    Debt/Equity Ratio
    3.1%

    TegoScience Inc. Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About A191420

    Founded
    2001
    Employees
    40
    CEO
    Saewha Jeon
    WebsiteView website
    www.tegoscience.com

    TegoScience Inc., a biotechnology-based cosmetics company, engages in the production and sale of skin cell therapy products from human epithelial cells in South Korea. The company’s products include Holoderm, Kaloderm, Rosmir, Neoderm, and Chemotide. It also offers skin regeneration substance products. In addition, the company provides contract research services. TegoScience Inc. was founded in 2001 and is based in Seoul, South Korea.

    South Korean Market Performance

    • 7 Days: -1.1%
    • 3 Months: 22.2%
    • 1 Year: 23.5%
    • Year to Date: 30.6%
    Over the past 7 days, the market has dropped 1.1% with the Materials sector contributing the most to the decline. In contrast to the last week, the market is actually up 24% over the past year. Earnings are forecast to grow by 22% annually. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading